![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Scott Waldman is currently the Chairman of the Department of Pharmacology and Experimental Therapeutics and the Director of the Division of Clinical Pharmacology. He is the Samuel MV Professor, Department of Medicine and Biochemistry and Molecular Pharmacology. Waldman’s research interests focus on molecular pathways underlying early intestinal tumorigenesis and their utility as novel targeted agents for managing patients with colorectal cancer. Waldman obtained his BSc degree in Biology from the University at Albany, his PhD degree in Anatomy from Thomas Jefferson University and his MD degree from Stanford University. He was a postdoctoral fellow at the University of Virginia and Stanford University in the Division of Clinical Pharmacology. He has received numerous honors and awards. He currently has 20 awarded patents and 30 patents pending related to novel diagnostic, therapeutic and immunological targets for gastrointestinal malignancies. He is a member of several editorial boards and scientific peer-review committees. Waldman has over 200 publications in various journals, including Proceedings of the National Academy of Science, Gastroenterology, Journal of Biological Chemistry and Journal of Clinical Investigation. Waldman has served on many councils and chaired NIH study sections. He is currently a member of the Osler Society and the College of Reviewers for the Canada Research Chairs Program. He is a past member of the American Board of Clinical Pharmacology, a past Regent of the American College of Clinical Pharmacology and a past President of the American Society for Clinical Pharmacology and Therapeutics.
Financial & competing interests disclosure
S Waldman is a paid consultant for Merck and is the Chair of the Scientific Advisory Board (uncompensated) for Targeted Diagnostics & Therapeutics, Inc. who has the license to commercialize the technology for lymph node staging discussed in this interview. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.